Logo image of XBIO

XENETIC BIOSCIENCES INC (XBIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XBIO - US9840156023 - Common Stock

2.33 USD
-0.11 (-4.51%)
Last: 12/15/2025, 6:20:51 PM
2.37 USD
+0.04 (+1.72%)
After Hours: 12/15/2025, 6:20:51 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to XBIO. XBIO was compared to 529 industry peers in the Biotechnology industry. XBIO has a great financial health rating, but its profitability evaluates not so good. XBIO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XBIO had negative earnings in the past year.
XBIO had a negative operating cash flow in the past year.
XBIO had negative earnings in each of the past 5 years.
XBIO had a negative operating cash flow in each of the past 5 years.
XBIO Yearly Net Income VS EBIT VS OCF VS FCFXBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M -50M

1.2 Ratios

XBIO has a Return On Assets (-57.59%) which is comparable to the rest of the industry.
XBIO's Return On Equity of -69.28% is in line compared to the rest of the industry. XBIO outperforms 55.95% of its industry peers.
Industry RankSector Rank
ROA -57.59%
ROE -69.28%
ROIC N/A
ROA(3y)-46.96%
ROA(5y)-50.4%
ROE(3y)-52.04%
ROE(5y)-55.19%
ROIC(3y)N/A
ROIC(5y)N/A
XBIO Yearly ROA, ROE, ROICXBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XBIO Yearly Profit, Operating, Gross MarginsXBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

7

2. Health

2.1 Basic Checks

XBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XBIO remains at a similar level compared to 1 year ago.
The number of shares outstanding for XBIO has been increased compared to 5 years ago.
XBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XBIO Yearly Shares OutstandingXBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
XBIO Yearly Total Debt VS Total AssetsXBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -48.83, we must say that XBIO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -48.83, XBIO is doing worse than 93.19% of the companies in the same industry.
XBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -48.83
ROIC/WACCN/A
WACC8.83%
XBIO Yearly LT Debt VS Equity VS FCFXBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

XBIO has a Current Ratio of 5.93. This indicates that XBIO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of XBIO (5.93) is better than 61.25% of its industry peers.
A Quick Ratio of 5.93 indicates that XBIO has no problem at all paying its short term obligations.
XBIO has a Quick ratio of 5.93. This is in the better half of the industry: XBIO outperforms 62.57% of its industry peers.
Industry RankSector Rank
Current Ratio 5.93
Quick Ratio 5.93
XBIO Yearly Current Assets VS Current LiabilitesXBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

XBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.85%, which is quite impressive.
Looking at the last year, XBIO shows a decrease in Revenue. The Revenue has decreased by -2.90% in the last year.
Measured over the past years, XBIO shows a very strong growth in Revenue. The Revenue has been growing by 162.66% on average per year.
EPS 1Y (TTM)34.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.78%
Revenue 1Y (TTM)-2.9%
Revenue growth 3Y29.17%
Revenue growth 5Y162.66%
Sales Q2Q%-18.79%

3.2 Future

XBIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.09% yearly.
The Revenue is expected to grow by 4.35% on average over the next years.
EPS Next Y19.04%
EPS Next 2Y-14.79%
EPS Next 3Y23.09%
EPS Next 5YN/A
Revenue Next Year13.64%
Revenue Next 2Y16.77%
Revenue Next 3Y4.35%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
XBIO Yearly Revenue VS EstimatesXBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
XBIO Yearly EPS VS EstimatesXBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XBIO Price Earnings VS Forward Price EarningsXBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XBIO Per share dataXBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as XBIO's earnings are expected to grow with 23.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.79%
EPS Next 3Y23.09%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

XENETIC BIOSCIENCES INC

NASDAQ:XBIO (12/15/2025, 6:20:51 PM)

After market: 2.37 +0.04 (+1.72%)

2.33

-0.11 (-4.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10
Earnings (Next)03-16 2026-03-16/amc
Inst Owners2.83%
Inst Owner Change-9.46%
Ins Owners0.82%
Ins Owner Change0%
Market Cap5.34M
Revenue(TTM)2.45M
Net Income(TTM)-3.08M
Analysts43.33
Price TargetN/A
Short Float %0.71%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.36%
Min EPS beat(2)19.66%
Max EPS beat(2)31.07%
EPS beat(4)2
Avg EPS beat(4)-69.67%
Min EPS beat(4)-233.33%
Max EPS beat(4)31.07%
EPS beat(8)6
Avg EPS beat(8)-27.59%
EPS beat(12)9
Avg EPS beat(12)-6.3%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.41%
Min Revenue beat(2)-13.19%
Max Revenue beat(2)-9.64%
Revenue beat(4)1
Avg Revenue beat(4)33.42%
Min Revenue beat(4)-19.71%
Max Revenue beat(4)176.22%
Revenue beat(8)3
Avg Revenue beat(8)20.54%
Revenue beat(12)7
Avg Revenue beat(12)34.11%
Revenue beat(16)11
Avg Revenue beat(16)46.12%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.18
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-2
EYN/A
EPS(NY)-3.39
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS1.07
BVpS1.94
TBVpS1.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -57.59%
ROE -69.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.96%
ROA(5y)-50.4%
ROE(3y)-52.04%
ROE(5y)-55.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.93
Quick Ratio 5.93
Altman-Z -48.83
F-Score5
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.78%
EPS Next Y19.04%
EPS Next 2Y-14.79%
EPS Next 3Y23.09%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.9%
Revenue growth 3Y29.17%
Revenue growth 5Y162.66%
Sales Q2Q%-18.79%
Revenue Next Year13.64%
Revenue Next 2Y16.77%
Revenue Next 3Y4.35%
Revenue Next 5YN/A
EBIT growth 1Y34.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.16%
EBIT Next 3Y-15.29%
EBIT Next 5YN/A
FCF growth 1Y46.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.03%
OCF growth 3YN/A
OCF growth 5YN/A

XENETIC BIOSCIENCES INC / XBIO FAQ

Can you provide the ChartMill fundamental rating for XENETIC BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to XBIO.


Can you provide the valuation status for XENETIC BIOSCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to XENETIC BIOSCIENCES INC (XBIO). This can be considered as Overvalued.


Can you provide the profitability details for XENETIC BIOSCIENCES INC?

XENETIC BIOSCIENCES INC (XBIO) has a profitability rating of 1 / 10.


How financially healthy is XENETIC BIOSCIENCES INC?

The financial health rating of XENETIC BIOSCIENCES INC (XBIO) is 7 / 10.